Inayat-ur-Rahman

Neopharma, a leading global pharmaceutical company based in the UAE and GlaxoSmithKline (GSK) the global science-led healthcare company, have announced the launch of the first ever locally produced batch of medicines, as a result of their partnership to create localization and manufacturing opportunities in the UAE.

Abu Dhabi has set out to become a pharmaceutical research, development and manufacturing hub within the MENA region, and this is another great step forward in achieving this aim.

This was stated by Mohamed Hamad Al Hameli, Undersecretary of the Department of Health at the event in Abu Dhabi.

“In doing so, the country will be better placed to meet the needs of patients through improved access to locally produced medicines”, he added.

The UK Ambassador to the UAE, Patrick Moody said “The launch is a fantastic example of what UK and UAE companies can achieve together. It is bringing jobs and expertise to the UAE, as well as better services for patients. I congratulate the Abu Dhabi Department of Health and the UK Department for International Trade for their support in making this happen.  It is another step forward in our shared ambition to work together to be global leaders in healthcare and life sciences.”  Dr B.R. Shetty, Founder and Chairman of Neopharma, said: “It is wonderful to witness another landmark moment in our collaboration with GSK. We are delighted to partner with GSK to be able to provide local patients better access to medicines. By manufacturing the medicine locally, Neopharma has reinforced its commitment to maintaining global quality and manufacturing standards that are complying to stringent regulatory requirements. In innovation science we are focusing on debilitating metabolic diseases, and immuno oncology with over 200 scientists working at Neopharma Japan site.”